Capivasertinib

Brand name: Truqap

E*

Score E* — Unproven but Suspected

This drug is suspected to be capable of causing liver injury, but there are no convincing cases in the medical literature.

Cases may have been reported to regulatory agencies, but specifics supportive of causality are not available. The agent is unproven, but suspected to cause liver injury.

Primary class Antineoplastic
Secondary class Breast CA, HR+, HER2-ve
FDA approval 2023
Search another medication

No article link available. Search directly at livertox.nih.gov.